Trials / Completed
CompletedNCT01375751
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Evolocumab | Administered by subcutaneous injection |
| BIOLOGICAL | Placebo | d by subcutaneous injection |
Timeline
- Start date
- 2011-08-02
- Primary completion
- 2012-05-16
- Completion
- 2012-05-16
- First posted
- 2011-06-17
- Last updated
- 2022-11-15
- Results posted
- 2015-09-29
Source: ClinicalTrials.gov record NCT01375751. Inclusion in this directory is not an endorsement.